financetom
Business
financetom
/
Business
/
Form 8.3
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Form 8.3
Nov 7, 2025 5:28 AM

LONDON--(BUSINESS WIRE)--

 

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the “Code”)

1. KEY INFORMATION

(a) Full name of discloser:

Qube Research & Technologies Limited

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

 

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Greencore Group plc ( GNCGF )

If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:

 

(e) Date position held/dealing undertaken:

For an opening position disclosure, state the latest practicable date prior to the disclosure

06-11-2025

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state “N/A”

BAKKAVOR GROUP PLC

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:

 

1p ordinary

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

0

0.00

0

0.00

(2) Cash-settled derivatives:

 

5,617,695

1.26

0

0.00

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

0

0.00

0

0.00

 

TOTAL:

5,617,695

1.26

0

0.00

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b) Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:

0

Details, including nature of the rights concerned and relevant percentages:

0

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a) Purchases and sales

Class of relevant security

Purchase/sale

 

Number of securities

Price per unit (GBp)

(b) Cash-settled derivative transactions

Class of relevant security

Product description

e.g. call option

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of securities

Exercise price per unit (GBp)

1p ordinary

equity swap

decreasing a long position

3041

230.00

1p ordinary

equity swap

decreasing a long position

1235

230.50

1p ordinary

equity swap

decreasing a long position

11154

231.00

1p ordinary

equity swap

decreasing a long position

10654

232.00

1p ordinary

equity swap

decreasing a long position

2927

233.00

1p ordinary

equity swap

decreasing a long position

259

233.50

1p ordinary

equity swap

decreasing a long position

543

234.00

1p ordinary

equity swap

decreasing a long position

2671

235.50

1p ordinary

equity swap

decreasing a long position

119

238.50

1p ordinary

equity swap

increasing a long position

492

231.50

1p ordinary

equity swap

increasing a long position

251

232.00

1p ordinary

equity swap

increasing a long position

1971

233.50

1p ordinary

equity swap

increasing a long position

1488

234.50

1p ordinary

equity swap

increasing a long position

1952

235.00

1p ordinary

equity swap

increasing a long position

282

236.00

1p ordinary

equity swap

increasing a short position

1331

232.00

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit (GBp)

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit
(GBp)

(ii) Exercise

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

0

0

0

0

 

0

(d) Other dealings (including subscribing for new securities)

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

0

 

0

0

0

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

 

None

 

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state “none”

 

None

 

(c) Attachments

Class of relevant security:

 

1p ordinary

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

0

0.00

0

0.00

(2) Cash-settled derivatives:

 

5,617,695

1.26

0

0.00

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

0

0.00

0

0.00

 

TOTAL:

5,617,695

1.26

0

0.00

0

Class of relevant security:

 

1p ordinary

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

0

0.00

0

0.00

(2) Cash-settled derivatives:

 

5,617,695

1.26

0

0.00

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

0

0.00

0

0.00

 

TOTAL:

5,617,695

1.26

0

0.00

1

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129. The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

Source: Qube Research & Technologies LTD

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Royalty Pharma to buy royalty interest in Amgen's lung cancer drug for up to $950 million
Royalty Pharma to buy royalty interest in Amgen's lung cancer drug for up to $950 million
Aug 25, 2025
(Reuters) -Royalty Pharma said on Monday it has signed a deal with BeOne Medicines to acquire a royalty interest in Amgen's drug for small cell lung cancer for up to $950 million. The deal gives Royalty Pharma access to roughly 7% of global net sales of the therapy, which won U.S. approval last year for patients with extensive-stage small cell...
BRIEF-Beigene And Unit Sign Royalty Purchase Agreement With Royalty Pharma PLC's Unit
BRIEF-Beigene And Unit Sign Royalty Purchase Agreement With Royalty Pharma PLC's Unit
Aug 25, 2025
Aug 25 (Reuters) - Beigene Ltd: * SAY CO, UNIT SIGN ROYALTY PURCHASE AGREEMENT WITH ROYALTY PHARMA INVESTMENTS 2023 ICAV, UNIT OF ROYALTY PHARMA PLC * SAYS AGREED TO SELL RIGHTS TO ROYALTIES ON IMDELLTRA SALES OUTSIDE CHINA TO ROYALTY PHARMA INVESTMENTS 2023 ICAV FOR $885 MILLION UPFRONT Source text Further company coverage: (Reporting by Beijing Newsroom) ...
FOCUS-Wall Street hires more senior bankers as growing confidence spurs deal rebound
FOCUS-Wall Street hires more senior bankers as growing confidence spurs deal rebound
Aug 25, 2025
* Hiring surge follows tariff-induced pause * Senior hires include Citigroup ( C/PN ) and UBS executives * Junior staff recruitment rose 200% in August, search firm says By Tatiana Bautzer, Saeed Azhar and Isla Binnie NEW YORK, Aug 25 (Reuters) - Wall Street banks have hired dozens of senior executives in recent months, as improved economic sentiment has spurred...
Market Chatter: Paramount Skydance Expected to Slash up to 3,000 Workers by November
Market Chatter: Paramount Skydance Expected to Slash up to 3,000 Workers by November
Aug 25, 2025
06:58 AM EDT, 08/25/2025 (MT Newswires) -- Paramount Skydance ( PSKY ) is set to lay off between 2,000 to 3,000 of its employees across various divisions by early November, Variety reported Friday, citing sources with knowledge of the company's plans. This comes shortly after the company closed its merger with Skydance this month and layoffs were expected as the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved